Related Experiment Videos
Thalidomide in patients with advanced multiple myeloma.
I Yakoub-Agha1, P Moreau, S Leyvraz
1Service des Maladies du Sang, CHU, Lille, France.
Summary
Thalidomide shows efficacy in advanced multiple myeloma patients. This study found a 45% response rate with generally moderate side effects, confirming its effectiveness.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Thalidomide's efficacy and safety in refractory multiple myeloma have been recently reported.
- This study assesses thalidomide in advanced multiple myeloma.
- The Intergroupe Franchophone du Myélome (IFM) reports preliminary experience with thalidomide.
Purpose of the Study:
- To evaluate the efficacy and tolerance of thalidomide in advanced multiple myeloma.
- To assess the response rate and side effects of thalidomide treatment.
Main Methods:
- 27 patients with advanced multiple myeloma received oral thalidomide (median 400 mg/day).
- All patients had active disease at baseline.
- 20 patients had previously undergone autologous transplantation.
Main Results:
- A 45% overall response rate was observed (12/27 patients).
- Responses included reductions in M-component levels (≥75% in 4 patients, ≥50% in 5, ≥25% in 3).
- Short-term side effects were generally moderate.
Conclusions:
- Thalidomide is an effective agent for patients with advanced multiple myeloma.
- The study confirms thalidomide's therapeutic role in this patient population.